Product Description
Daclatasvir is an orally available antiviral agent that inhibits the NS5A region of the hepatitis C virus (HCV) and was used in combination with other oral antiviral agents to treat chronic hepatitis C before its withdrawal in 2019. Daclatasvir is an orally available inhibitor of the hepatitis C virus (HCV) non-structural protein 5A (NS5A) replication complex, with potential activity against HCV. Although the exact mechanism of action of daclatasvir has yet to be fully determined, this agent, upon oral administration and after intracellular uptake, appears to bind to domain I of the NS5A protein. (Sourced from: https://pubchem.ncbi.nlm.nih.gov/compound/Daclatasvir)
Mechanisms of Action: HCV-NS5A Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Approved
Approved Countries: Argentina | Australia | Bangladesh | Belgium | Brazil | Canada | Chile | Colombia | Dominican Republic | Egypt | European Medicines Agency | Finland | France | Germany | Hungary | India | Indonesia | Ireland | Italy | Japan | Korea | Lebanon | Lithuania | Malaysia | Netherlands | New Zealand | Pakistan | Peru | Philippines | Poland | Portugal | Russia | Saudi Arabia | Spain | Sweden | Taiwan | Turkey | Ukraine | United Kingdom | Uruguay | Vietnam
Approved Indications: None
Known Adverse Events: None
Company: Bristol-Myers Squibb
Company Location: NEW YORK NY 10016
Company CEO: Giovanni Caforio
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: China, Unknown Location
Active Clinical Trial Count: 3
Highest Development Phases
Phase 3: Hepatitis C, Chronic
Phase 1: Hepatitis C
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| CTR20132226 | P3 |
Active, not recruiting |
Hepatitis C, Chronic |
None |
|
| CTR20202688 | P1 |
Not yet recruiting |
Hepatitis C |
None |
|
| CTR20132850 | P3 |
Active, not recruiting |
Hepatitis C, Chronic |
None |